Extracerebral Decarboxylase Inhibitor

Extracerebral decarboxylase inhibitor is an inhibitory enzyme. It is used to inhibit the decarboxylation of L-DOPA to Dopamine outside the brain, i.e. in the blood. This is primarily co-administered with L-DOPA to combat Parkinson's disease. Administration can prevent common side-effects, such as nausea and vomiting, as a result of interaction with D2 receptors in the vomiting center (or cheomoreceptor trigger zone) located outside the blood–brain barrier.^[1]

Examples of extracerebral decarboxylase inhibitors include Carbidopa and Benserazide.

References

↑ Calne, D. B.; Reid, J. L.; Vakil, S. D.; Rao, S.; Petrie, A.; Pallis, C. A.; Gawler, J.; Thomas, P. K. et al. (1971). "Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa". British Medical Journal 3 (5777): 729–732. doi:10.1136/bmj.3.5777.729. PMID 4938431.

0.00

(0 votes)

[1] Calne, D. B.; Reid, J. L.; Vakil, S. D.; Rao, S.; Petrie, A.; Pallis, C. A.; Gawler, J.; Thomas, P. K. et al. (1971). "Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa". British Medical Journal 3 (5777): 729–732. doi:10.1136/bmj.3.5777.729. PMID 4938431.